2026-09-09T02:02:24Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/119062026-07-09T00:05:17Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

Sanz Solas, Antonio Saiz Rodríguez, Miriam Calvo Simal, Sara Rodríguez-Veiga, Rebeca Solana-Altabella, Antonio Montesinos, Pau Labrador Gómez, Jorge 2026-07-08T10:45:44Z 2026-07-08T10:45:44Z 2025-08 0939-5555 https://hdl.handle.net/10259/11906 10.1007/s00277-025-06543-3 1432-0584 This meta-analysis, comprising 24 studies, evaluated the efficacy of venetoclax (VEN) in combination with hypomethylat-ing agents (HMAs), including azacitidine (AZA) and decitabine (DEC), in untreated patients with acute myeloid leukemia (AML), comparing outcomes from clinical trials and real-world practice. No significant difference in composite complete response (CRc) rates was observed between clinical trials (52%, 95% CI: 39–65%) and real-world studies (67%, 95% CI: 47–87%). However, overall survival (OS) was significantly longer in clinical trials (13.98 months, 95% CI: 11.89–16.07) compared to real-world cohorts (9.35 months, 95% CI: 8.46–10.23; p < 0.005). In real-world studies, the VEN + HMA combination was associated with a significantly higher CRc rate (67%, 95% CI: 48–85%) compared to HMA monotherapy (17%, 95% CI: 13–21%; p < 0.005), although no significant difference in OS was observed between these groups (9.35 vs. 9.38 months; p = 0.964). These findings highlight the need to optimize the implementation of VEN + HMA regimens in clinical practice, as real-world outcomes remain inferior to those reported in clinical trials. A.S.S contract was funded by Fundación hna, 2nd edition of the Scientific Health Research Award. M.S.R. contract was supported by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation, through the Sara Borrell Program (CD21/00022). eng Springer Annals of Hematology. 2025, V. 14, n. 9, p. 4505-4514 https://doi.org/10.1007/s00277-025-06543-3 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Cáncer-Tratamiento Leucemia mieloide Cancer-Treatment Myeloid leukemia Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Annals of Hematology 104 9 4505 4514